



Experimental Treatment of Mucinous Peritoneal Metastases Using Patient-Derived Xenograft Models

Karianne Giller Fleten^{a,b}, Christin Lund-Andersen^{a,b}, Stein Waagene^a, Torveig Weum Abrahamsen^a, Yrr Mørch^c, Kjetil Boye^{a,d}, Annette Torgunrud^a, Kjersti Flatmark^{a,b,*}

^a Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway

^b Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Norway

^c Department of Biotechnology and Nanomedicine, SINTEF, AS, Trondheim, Norway

^d Department of Oncology, Oslo University Hospital, Oslo, Norway

ARTICLE INFO

Article history:

Received 13 March 2020

Received in revised form 23 April 2020

Accepted 24 April 2020

ABSTRACT

Mucinous peritoneal metastases (PM) generally respond poorly to systemic treatment, and there is a clear unmet need for new treatment strategies to improve survival and quality of life for patients with PM. In this work, the growth inhibitory effect of five drugs (oxaliplatin (OXA; 5 mg/kg), irinotecan (IRI; 60 mg/kg), cabazitaxel (CBZ; 15 or 30 mg/kg), regorafenib (REG; 10, 30 or 60 mg/kg), and capecitabine (CAP; 359 or 755 mg/kg) was investigated in three orthotopic patient-derived xenograft models that mimic mucinous PM.

Drugs were administered intraperitoneally (i.p.) as monotherapy weekly for 4 weeks (OXA, IRI), as one single i.p. injection (CBZ), or orally (REG, CAP) daily 5 of 7 days per week for four weeks, and i.p. tumor growth and survival were monitored and compared between treatment groups. The i.p. administered drugs (OXA, IRI, CBZ) had the strongest growth inhibitory effect, with OXA being most efficacious, completely inhibiting tumor growth in the majority of the animals. CBZ and IRI also strongly inhibited tumor growth, but with more variation in efficacy between the models. A moderate reduction in tumor growth was observed in all models treated with REG, while CAP had little to no growth inhibitory effect. Targeted next-generation-sequencing has identified mutational profiles typically associated with PM (mutations in *KRAS*, *GNAS*, and *BRAF* oncogenes), supporting the representativeness of the models. The results presented in this work support the continued exploration of i.p. treatment protocols for PM, with OXA remaining and CBZ emerging as particularly interesting candidates for further studies.

Introduction

Peritoneal metastases represent an important therapeutic challenge, since patients generally respond poorly to systemic chemotherapy and targeted treatments [1]. A possible explanation could be that cancers with unfavorable molecular subtypes tend to metastasize to the peritoneal surface. Indeed, colorectal cancers (CRC) with mucinous and signet ring cell differentiation often give rise to peritoneal metastases (PM), and these tumors exhibit poor responses to several of the commonly used chemotherapeutic drugs [2,3]. Another strictly peritoneal mucinous entity is pseudomyxoma peritonei (PMP), which is a rare cancer commonly arising from mucinous tumors of the appendix, and which is also similarly poorly responsive to systemic chemotherapy [4,5]. Locoregional treatment involving cytoreductive surgery (CRS) and intraperitoneal chemotherapy

represents standard-of-care in resectable cases, but when locoregional treatment fails and for patients who are not eligible for such treatment, new treatment options are needed [6–9].

We have generated orthotopic patient-derived xenograft models that mimic mucinous PM, and that were shown to closely resemble the original disease with respect to growth pattern and protein expression [10,11]. We previously investigated single intraperitoneal (i.p.) injections of two drugs that are commonly used as components of hyperthermic intraperitoneal chemotherapy (HIPEC), mitomycin C (MMC) and oxaliplatin (OXA), identifying MMC as the more efficacious drug compared to OXA when administered as a single i.p. injection [12]. In this study, we investigated drugs that are part of standard systemic chemotherapy in CRC; OXA, irinotecan (IRI) and capecitabine (CAP); and included two less commonly used drugs in this setting, cabazitaxel (CBZ) and regorafenib (REG).

* Address all correspondence to: Kjersti Flatmark, Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Montebello, 0310, Oslo, Norway.

E-mail address: Kjersti.Flatmark@rr-research.no. (K. Flatmark).

Materials and Methods

In Vivo Experiments

All procedures and experiments involving animals were approved by the Norwegian Food Safety Authority (application ID #11836, #11946, and #18209), and were conducted according to the recommendations of the European Laboratory Animals Science Association. Female athymic foxn1tm were bred at Department of Comparative Medicine, Oslo University Hospital, and kept in a specific pathogen-free environment at constant temperature (22 ± 1 °C) and humidity (62 ± 5%), 15 air changes/hour and a 12-hour light/dark cycle. Food and water were supplied ad libitum, and the mice were given paper and card board houses for environmental stimulation. A maximum of 10 mice were housed in each cage. The model establishment was previously described [10,11], and the models PMP-2, PMCA-1 and PMCA-3 were used in these experiments. All models were established by implanting peritoneal tissue samples collected at the time of CRS-HIPEC. PMP-2 and PMCA-3 were derived from patients with appendiceal primaries, whereas the PMCA-1 patient had a primary rectal carcinoma. PMP-2 was classified as peritoneal mucinous carcinomatosis intermediate histological type (PMCA-I) based on the Ronnett classification [13], while PMCA-3 was a high grade PMP with signet ring cell differentiation. For treatment experiments 125–200 µl mucinous ascites was injected (i.p.), and treatments were initiated the following day to simulate the clinical situation after CRS with a very low remaining tumor load intraabdominally. Mice were randomly assigned to treatment groups of 6 mice. The mice were routinely examined by experienced animal technicians, and sacrificed when abdominal distension was clearly visible, at which time approximately 4–5 g of mucinous tumor tissue would be weighed at autopsy. Occasionally, the tumor had a more solid growth pattern with a necrotic core, and in these cases the mice developed cachexia, necessitating sacrifice. Animals with no sign of tumor growth were sacrificed 100 days (range 100–103 days) after experiment initiation, which in all experiments was at least twice the median time of the survival of the vehicle treated animals. Tumor growth/response was quantified by calculating a growth index [12], combining the key parameters survival time (in days) and tumor load at the time of sacrifice (in g), using the equation:

$$\text{Growth index} = \text{tumor weight} + ((T_{\text{total}} - T_A) / T_{\text{Total}}) \times 10.$$

where T_A is the time from start of the experiment until sacrifice of the animal, and T_{Total} is the total duration of the experiments.

Of the 184 animals included in the experiments, seven were excluded from analysis for the following reasons: wrong treatment given ($n = 1$) (PMP-2), mucin not weighed ($n = 5$) (PMCA-3), development of ascites with no visible tumor growth ($n = 1$) (PMP-2).

Drugs

OXA (Fresenius Kabi, Germany) was diluted in 5% glucose; i.p. injections of 5 mg/kg were administered weekly for 4 weeks. CBZ (TXD-258, BioChemPartner Co. Ltd., Shanghai, China) was dissolved in polysorbate 80 (40 mg/ml), diluted in 13% ethanol to a working concentration of 10 mg/ml, and further diluted in 0.9% NaCl; i.p. injections of 15 and 30 mg/kg were administered once. IRI (Pfizer, New York, NY, USA), (prodrug that is metabolized to SN-38 [14]) was diluted in 0.9% saline; i.p. injections of 60 mg/kg were administered weekly for 4 weeks. Injection volumes were in the range of 200–250 µl, according to body weight (10 µl/g mouse). REG (kindly donated by Bayer) was dissolved in DMSO, further diluted in PEG400, and administered by oral gavage 5 of 7 days per week for 4 weeks. Tablets of CAP (Roche, Hertfordshire, UK) (prodrug that is metabolized to 5-fluorouracil [15]) were suspended in a vehicle consisting of 50 mM citrate buffer and 4.67% (w/v) arabic gum (pH 6.0), and 359 or 755 mg/kg was administered by oral gavage 5 of 7 days per week for 4 weeks. Vehicle treated animals received DMSO/PEG400 5 of 7 days per

week for 4 weeks corresponding to regorafenib treatment. All of the drugs and doses used in the experiments were well tolerated, and no toxicity, defined as a weight reduction of more than 15%, was observed.

Drug regimens were chosen based on the maximum tolerable doses of the drugs previously published or based on in-house experience. For CAP, 359 mg/kg was chosen based on previous experience of efficacy in another model [16], but as this dose had limited effect, experiments were also performed with the defined maximum tolerable dose of 755 mg/kg [17]. The treatment regimens were chosen based on the recommended administration route and frequency for each drug.

DNA Sequencing

Tumor tissue samples from PDX models were homogenized and disrupted using TissueLyzer LT from QIAGEN. DNA was then extracted from the lysate using the NucleoSpin Tissue kit (Macherey Nagel, Düren, Germany). DNA concentrations and purity were evaluated using ThermoFisher NanoDrop spectrophotometer, and the $\text{Abs}_{260/280} > 1.8$ for all the samples. Targeted DNA sequencing was performed using the Ion Torrent PGM Personal Genome Machine and the Ion AmpliSeq™ Cancer Hotspot Panel v2 (Thermo Fisher Scientific, Waltham, MA, USA), covering ~2800 hotspot mutations in 50 cancer related genes. The Torrent Suite Variant Caller, with the manufacturer's recommended settings, was used to generate single nucleotide variants and small insertions/deletions with a variant allele frequency threshold of two percent. The sequencing depth exceeded 500× for 98% of all amplicons (median depth of 4376×). Every detected mutation was manually reassessed using Integrative Genomics Viewer and functionally annotated with ANNOVAR [18], using RefSeq as the underlying gene model and information from the 1000 Genomes Project (1000genomes.org) and the Catalogue of Somatic Mutations in Cancer (cancer.sanger.ac.uk/cosmic).

Statistical Analyses

Statistical analyses were conducted using GraphPad Prism v7 (GraphPad Software, LaJolla, California, USA) or SPSS 21 (IBM, Armonk, NY, USA), and Student's t-tests were performed to compare treatment groups. p-values < 0.05 were considered statistically significant.

Results

All vehicle treated animals developed tumor. The time between tumor implantation and sacrifice in vehicle-treated animals was relatively similar in the three models, with a mean of 37, 38 and 44 days for PMCA-3, PMP-2 and PMCA-3, respectively.

In the PMP-2 model, OXA was the most efficacious drug, and 5 of 6 mice did not develop tumor growth, with a mean reduction of growth index of 97% compared to vehicle treatment. CBZ also had a strong growth inhibitory effect, with a mean reduction in growth index of 86% ($P < .001$), but no dose–response relationship was observed (Figure 1A). Of the 11 animals receiving CBZ, 6 did not develop tumor growth (Table 1). Moderate growth inhibition (20–29%) was observed with IRI, CAP and REG ($P < .05$). One animal in the CAP group did not develop tumor, otherwise all animals were sacrificed because of tumor growth.

In the PMCA-1 model, OXA was again the most efficacious drug, and none of the 6 mice receiving the treatment developed tumor (Figure 1B). Two mice were euthanized after 32 and 74 days due to snout infection and edema respectively, but no tumor was detected in the abdomen at the time of sacrifice. CBZ also had a strong growth inhibitory effect with a trend towards a dose–response effect ($P = .06$), with 66% and 99% reduction of growth inhibition ($P < .01$) after administration of 15 and 30 mg/kg, respectively. Complete growth control was observed in 5/6 mice and 3/6 mice for 30 mg/kg and 15 mg/kg, respectively. IRI also had a strong growth inhibitory effect, with a reduction in growth index of 72% ($P < .001$). One of six mice treated with IRI did not develop tumor, while the remaining mice either lived until the end of the experiment or close




Figure 1. Growth index of (A) PMP-2, (B) PMCA-1 and (C) PMCA-3 treated with oxaliplatin (OXA), irinotecan (IRI), cabazitaxel (CBZ), regorafenib (REG) and capecitabine (CAP). Numbers on the X-axis indicate dose in mg/kg. * $P < .05$. Error bars indicate standard error of the mean (SEM).

to the end. For REG 10 mg/kg, all animals developed tumor, and a moderate growth inhibition was observed, with a reduction in growth index of 29% ($P < .001$) (Table 1). CAP was the least efficacious drug, with no difference in growth index compared to vehicle treatment (Figure 1B).

PMCA-3 was the least responsive model, and except for OXA, only moderate tumor growth inhibition was achieved (Figure 1C). None of the five mice treated with OXA developed tumor. IRI and CBZ were equally effective in inhibiting tumor growth, with a mean reduction of the growth index to 53% for IRI ($P < .001$) and 39 and 41% for mice treated with 15 and 30 mg/kg CBZ, respectively ($P < .001$). Moderate growth inhibition was also observed with REG, with a reduction in growth index of 22% ($P = .003$) and 15% ($P = .02$) after treatment with 30 and 60 mg/kg REG, respectively. One mouse treated with 30 mg/kg REG did not develop tumor, otherwise all animals were sacrificed due to tumor growth (Table 1). A small reduction of growth index was observed in mice treated with CAP with a 14% ($P = .014$) and 11% ($P = .139$) reduction in growth index after administration of 359 and 755 mg/kg, respectively (Figure 1C).

Mutation Analyses

PMP-2 and PMCA-3 both had mutated *GNAS* (R201C), while mutated *KRAS* (G12V and G12A) was present in PMP-2 and PMCA-1. In addition,

mutations in *BRAF* (V600E) and *CTNNB1* (D32G) were detected in PMCA-3 and a *TP53* (R248Q) was detected in PMCA-1 (Table 2).

Discussion

Single i.p. injections of OXA 5 and 10 mg/kg were previously investigated in the same models with a modest inhibitory effect on tumor growth [12], and for this study the schedule was changed to include four weekly administrations of 5 mg/kg. The strong growth inhibitory effect observed was interesting, highlighting the importance of the treatment schedule. The results from the PRODIGE7 trial presented at ASCO in 2018 [19] suggested that adding OXA-based HIPEC to CRS in PM-CRC did not improve the survival compared to CRS alone, leading to questions regarding the benefit of HIPEC in the treatment of PM-CRC [19,20]. OXA exposure time has been shown to be associated with response in vitro, and the 30-minute OXA exposure in the PRODIGE7 trial may have been insufficient to cause effective tumor cell killing [20,21]. Our results suggest that repeated exposure might improve drug efficacy, and points to OXA having a strong direct anti-tumor effect in these models upon administration in the peritoneal cavity.

Single injections of CBZ efficaciously inhibited tumor growth, and at the highest doses exhibited similar effects as were previously observed with

Table 1

In vivo tumor growth in three models treated with vehicle, oxaliplatin, irinotecan, cabazitaxel, regorafenib or capecitabine with number of animals with tumor growth, survival, amount of tumor and number of animals excluded and for what reason

	Vehicle	Oxaliplatin (mg/kg)	Irinotecan (mg/kg)	Cabazitaxel (mg/kg)		Regorafenib (mg/kg)			Capecitabine (mg/kg)	
		5	60	15	30	10	30	60	359	755
PMP-2										
Tumor growth/total number of animals	12/12	1/6	6/6	3/6	2/5		5/5	6/6	5/6	
Survival (days, mean)	39	100	68	100	97		62	57	67	
Tumor (g), mean (SEM)	4.3 (0.4)	0.4 (0.4)	4.6 (0.3)	1.2 (0.7)	1.4 (0.9)		2.6 (0.9)	4.1 (0.8)	4.1 (0.8)	
# of mice excluded					1*		1***			
PMCA-1										
Tumor growth/total number of animals	18/18	0/6	5/6	3/6	1/6	12/12			6/6	
Survival (days, mean)	44	84	96	91	103	63			51	
Tumor (g), mean (SEM)	5.3 (0.3)	0 (0)	2.6 (1.0)	2.3 (0.9)	0.1 (0.1)	4.3 (0.4)			5.70 (0.3)	
PMCA-3										
Tumor growth/total number of animals	24/24	0/5	6/6	9/10	5/5		10/11	6/6	11/11	5/5
Survival (days, mean)	37	100	74	68	75		51	46	45	44
Tumor (g), mean (SEM)	4.7 (0.3)	0	2.8 (0.6)	3.6 (0.5)	4.0 (0.5)		3.6 (0.5)	3.9 (0.3)	4.0 (0.4)	4.2 (0.4)
# of mice excluded		1**			1**		1**		1**	1**

(SEM, Standard error of the mean)

* Wrong treatment given.

** Mucin not weighed.

*** No tumor growth, only ascites.

Table 2
Overview over genes mutated in the PMP-2, PMCA-1 and PMCA-3 models

	<i>KRAS</i>	<i>GNAS</i>	<i>BRAF</i>	<i>TP53</i>	<i>CTNNB1</i>
PMP-2	p.G12V	p.R201C	wt	wt	wt
PMCA-1	p.G12A	wt	wt	p.R248Q	wt
PMCA-3	wt	p.R201C	p.V600E	wt	p.D32G

single i.p. injections of MMC [12]. CBZ is a member of the taxane family of microtubuli inhibitors, preventing cell division by stabilizing the microtubuli [22]. It is approved for treatment of hormone refractory prostate cancer following docetaxel-based treatment, but ongoing clinical trials are investigating CBZ in other cancer types as well [23]. In metastatic CRC (mCRC), a phase IIb trial was terminated because of lack of responses to intravenous administration in the first 10 included patients (NCT02204332). The strong growth inhibition observed in our experiments suggests a potential opportunity for CBZ in peritoneal disease, possibly administered i.p. Interestingly, i.p. injections of IRI also inhibited tumor growth in all models. High expression of topoisomerase 1, which is associated with response to IRI [24] was frequently detected in PM-CRC (54% in a cohort of 465 cases) and also in PMP (63% in a cohort of 43 cases) [25,26], providing a molecular rationale to expect efficacy of IRI in peritoneal disease. IRI is a component of standard-of-care systemic treatment for mCRC, but has not been extensively administered in i.p. treatment protocols [5,27,28]. Experimental results have suggested favorable treatment responses and less toxicity with i.p. compared to intravenous injection of IRI, highlighting the potential for locoregional treatment [14]. When used in combination with OXA during HIPEC, no increase in survival was observed for patients receiving the combination compared to OXA alone [29].

Significant growth inhibition was observed upon oral administration of REG in all the investigated models, but with no clear dose response effects. REG is a multi-tyrosine kinase inhibitor targeting angiogenic, stromal and oncogenic receptor tyrosine kinases, and is approved for treatment of mCRC [30,31]. REG has a short half-life, thus the requirement for daily administration of the drug. Treatment was stopped after 4 weeks, and since it has previously been observed that REG will inhibit tumor growth only on treatment, complete responses would not be expected [31]. Prolongation of the treatment period would have been expected to lengthen the inhibition of tumor growth. A possible combination strategy for REG is together with IRI, which has previously been shown to result in increased progression-free survival in patients with mCRC [32]. Interestingly, very encouraging results have also been observed with REG in combination with nivolumab in microsatellite stable mCRC in the recently reported REGONIVO trial, suggesting a novel opportunity for systemic treatment in PM-CRC [33].

The fluoropyrimidine, CAP, was the least efficacious drug in our models, having either a weak or no inhibitory effect on tumor growth. Fluoropyrimidines are included as a backbone of mCRC treatment, typically in combination with OXA or IRI [34]. Intravenous administration of 5-fluorouracil is also by many centers included concomitantly with HIPEC in patients with PMP and PM-CRC in combination with MMC or OXA [35,36]. In line with our observations, fluoropyrimidine monotherapy is not extensively administered in this setting, and is not expected to be highly efficacious.

The growth inhibitory responses varied between the models, with PMP-2 and PMCA-1 being more responsive than the PMCA-3 model. The PMCA-3 model, being a high-grade mucinous cancer with signet ring cell differentiation, mimics an aggressive phenotype, which could contribute to explain the observed differences. *KRAS* and *GNAS* mutations were the most frequent mutations observed in our models, both being common mutations in PM-CRC and PMP, respectively [25,26], indicating that the PDX models are representative of the original disease and relevant models for investigating drug responses. None of the mutations detected in our models are predictive biomarkers for the drugs investigated in this study. *KRAS* and *GNAS* mutations are both associated with poor survival in patients with CRC and PMP [7,37,38], and treatments that exhibit efficacy in models

with these genomic aberrations could potentially have an impact on a large patient group. Mutated *KRAS* has generally been considered to be undruggable, but efforts to develop drugs targeting *KRAS* have been extensive. Recently, a novel small molecule inhibitor of *KRAS* G12C (AMG 510) was shown to induce stable disease or partial responses in the majority of patients with advanced solid tumors receiving the treatment [39,40]. With *KRAS* mutations being prevalent in PM, efficacious targeting of mutated *KRAS* would represent an important therapeutic breakthrough for mutant PM cases.

In this study, OXA, CBZ and IRI administered by i.p. injection, all resulted in substantial growth inhibition, supporting the concept of locoregional administration of cytotoxic drugs in the peritoneal cavity. In contrast, the orally administered drugs, REG and CAP, were less efficacious, all though REG had an apparent inhibitory effect as long as it was being administered, and could be considered in combinatory protocols. There is a clear unmet need for new treatments for patients with PM-CRC and PMP, and based on the current work, OXA remains and CBZ emerges as particularly interesting candidates for further studies. We are currently investigating nanoparticle-based delivery of these drugs for i.p. administration.

Acknowledgements

KGF and CL-A are postdoctoral fellows of the Norwegian Cancer Society (Grant No. [197837]). This work was also supported by funding from the National Organization for Rare Disorders (NORD) through Appendix Cancer Pseudomyxoma Peritonei (ACPPM) Research Foundation.

Conflict of Interest

Bayer AG provided regorafenib and research support for the study.

Author Contributions

KGF: Investigation, formal analysis, visualization, writing original draft. **CLA:** Formal analysis, investigation. **SW:** Investigation. **TWA:** Resources. **YM:** Resources. **KB:** Conceptualization. **AT:** Formal analysis, investigation. **KF:** Conceptualization, methodology, writing reviewing and editing, supervision, funding acquisition. All authors approved the manuscript.

References

- [1] K. Waite, H. Youssef, The role of neoadjuvant and adjuvant systemic chemotherapy with cytoreductive surgery and heated intraperitoneal chemotherapy for colorectal peritoneal metastases: a systematic review, *Ann. Surg. Oncol.* 24 (3) (2017) 705–720.
- [2] N. Hugen, C.J.H. van de Velde, J.H.W. de Wilt, I.D. Nagtegaal, Metastatic pattern in colorectal cancer is strongly influenced by histological subtype, *Ann. Oncol.* 25 (3) (2014) 651–657.
- [3] L.J. Mekenkamp, K.J. Heesterbeek, M. Koopman, J. Tol, S. Teerenstra, S. Venderbosch, et al., Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer, *Eur. J. Cancer* 48 (4) (2012) 501–509.
- [4] N.J. Carr, T.D. Cecil, F. Mohamed, L.H. Sobin, P.H. Sugarbaker, S. Gonzalez-Moreno, et al., A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process, *Am. J. Surg. Pathol.* 40 (1) (2016) 14–26.
- [5] C.-F. Chen, C.-J. Huang, W.-Y. Kang, J.-S. Hsieh, Experience with adjuvant chemotherapy for pseudomyxoma peritonei secondary to mucinous adenocarcinoma of the appendix with oxaliplatin/fluorouracil/leucovorin (FOLFOX4), *World J Surg Oncol* 6 (2008) 118.
- [6] S. Hiraide, K. Komine, Y. Sato, K. Ouchi, H. Imai, K. Saijo, et al., Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei, *Int. J. Clin. Oncol.* 25 (4) (2020) 774–781.
- [7] F. Pietrantonio, R. Berenato, C. Maggi, M. Milione, F. Perrone, et al., *GNAS* mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study, *J. Transl. Med.* 14 (2016) 125.
- [8] P.H. Sugarbaker, New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? *Lancet Oncol* 7 (1) (2006) 69–76.
- [9] D. Elias, J.H. Lefevre, J. Chevalier, A. Brouquet, F. Marchal, J.M. Classe, et al., Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin, *J. Clin. Oncol.* 27 (5) (2009) 681–685.
- [10] K. Flatmark, B. Davidson, A. Kristian, H.T. Stavnes, M. Førsund, W. Reed, Exploring the peritoneal surface malignancy phenotype—a pilot immunohistochemical study of

- human pseudomyxoma peritonei and derived animal models, *Hum. Pathol.* 41 (8) (2010) 1109–1119.
- [11] K. Flatmark, W. Reed, T. Halvorsen, O. Sorensen, J.N. Wiig, S.G. Larsen, et al., Pseudomyxoma peritonei—two novel orthotopic mouse models portray the PMCA-I histopathologic subtype, *BMC Cancer* 7 (2007) 116.
- [12] K. Flatmark, I.J. Guldvik, H. Svensson, K.G. Fleten, V.A. Florenes, W. Reed, et al., Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies, *Int. J. Cancer* 133 (6) (2013) 1497–1506.
- [13] B.M. Ronnett, H. Yan, R.J. Kurman, B.M. Shmookler, L. Wu, P.H. Sugarbaker, Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis, *Cancer* 92 (1) (2001) 85–91.
- [14] S. Guichard, E. Chatelut, I. Lochon, R. Bugat, M. Mahjoubi, P. Canal, Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in mice, *Cancer Chemother. Pharmacol.* 42 (2) (1998) 165–170.
- [15] H. Ishitsuka, Capecitabine: preclinical pharmacology studies, *Investig. New Drugs* 18 (4) (2000) 343–354.
- [16] S. Folkvord, K. Flatmark, T. Seierstad, K. Roe, H. Rasmussen, A.H. Ree, Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity? *Radiother. Oncol.* 86 (3) (2008) 428–434.
- [17] I. Ninomiya, I. Terada, T. Yoshizumi, T. Takino, N. Nagai, A. Morita, et al., Anti-metastatic effect of capecitabine on human colon cancer xenografts in nude mouse rectum, *Int. J. Cancer* 112 (1) (2004) 135–142.
- [18] H. Yang, K. Wang, Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR, *Nat. Protoc.* 10 (10) (2015) 1556–1566.
- [19] Quenet, F., Elias, D., Roca, L., Goere, D., Ghouti, L., Pocard, M., et al., *A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7*. *J. Clin. Oncol.* 2018. 36(18_suppl): p. LBA3503-LBA3503.
- [20] A. Königsrainer, B. Rau, Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): don't throw the baby out with the bathwater, *Pleura Peritoneum* 3 (4) (2018) 20180131.
- [21] M.N. Kirshtein, S.A. Root, M.M. Moore, K.M. Wieman, B.W. Williams, P.A. Jacobson, et al., Exposure-response relationships for oxaliplatin-treated colon cancer cells, *Anti-Cancer Drugs* 19 (1) (2008) 37–44.
- [22] P. Vriegnaud, D. Semiond, P. Lejeune, H. Bouchard, L. Calvet, C. Combeau, et al., Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors, *Clin. Cancer Res.* 19 (11) (2013) 2973–2983.
- [23] C.J. Paller, E.S. Antonarakis, Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer, *Drug Des Devel Ther* 5 (2011) 117–124.
- [24] M.S. Braun, S.D. Richman, P. Quirke, C. Daly, J.W. Adlard, F. Elliott, et al., Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial, *J. Clin. Oncol.* 26 (16) (2008) 2690–2698.
- [25] W.S. El-Deiry, N. Vijayvergia, J. Xiu, A. Scicchitano, B. Lim, N.S. Yee, et al., Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites, *Cancer Biol Ther* 16 (12) (2015) 1726–1737.
- [26] E.M. Gleeson, R. Feldman, B.L. Mapow, L.T. Mackovick, K.M. Ward, W.F. Morano, et al., Appendix-derived pseudomyxoma peritonei (PMP): molecular profiling toward treatment of a rare malignancy, *Am. J. Clin. Oncol.* 41 (8) (2018) 777–783.
- [27] J. Franko, Q. Shi, C.D. Goldman, B.A. Pockaj, G.D. Nelson, R.M. Goldberg, et al., Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841, *J. Clin. Oncol.* 30 (3) (2012) 263–267.
- [28] L. März, P. Piso, Treatment of peritoneal metastases from colorectal cancer, *Gastroenterol Rep* 3 (4) (2015) 298–302.
- [29] F. Quenet, D. Goéré, S.S. Mehta, L. Roca, F. Dumont, M. Hessissen, et al., Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis, *Ann. Surg.* 254 (2) (2011) 294–301.
- [30] A. Grothey, E.V. Cutsem, A. Sobrero, S. Siena, A. Falcone, M. Ychou, et al., Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial, *Lancet* 381 (9863) (2013) 303–312.
- [31] S.M. Wilhelm, J. Dumas, L. Adnane, M. Lynch, C.A. Carter, G. Schutz, et al., Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity, *Int. J. Cancer* 129 (1) (2011) 245–255.
- [32] H.K. Sanoff, R.M. Goldberg, A. Ivanova, S. O'Reilly, S.S. Kasbari, R.D. Kim, et al., Multi-center, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer, *Cancer* 124 (15) (2018) 3118–3126.
- [33] S. Fukuoka, H. Hara, N. Takahashi, T. Kojima, A. Kawazoe, M. Asayama, et al., Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603), *J. Clin. Oncol.* 37 (15_suppl) (2019) 2522.
- [34] S. Kopetz, G.J. Chang, M.J. Overman, C. Eng, D.J. Sargent, D.W. Larson, et al., Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy, *J. Clin. Oncol.* 27 (22) (2009) 3677–3683.
- [35] J.S. Levitz, P.H. Sugarbaker, S.M. Lichtman, E.A. Brun, Unusual abdominal tumors, *J. Clin. Oncol.* 22 (8) (2004) 1518–1520.
- [36] A.L. Farquharson, N. Pranes, G. Witham, R. Swindell, M.B. Taylor, A.G. Renehan, et al., A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei, *Br. J. Cancer* 99 (4) (2008) 591–596.
- [37] E. Van Cutsem, C.H. Kohne, I. Lang, G. Folprecht, M.P. Nowacki, S. Cascinu, et al., Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status, *J. Clin. Oncol.* 29 (15) (2011) 2011–2019.
- [38] F. Pietrantonio, F. Perrone, A. Mennitto, E.M. Gleeson, M. Milione, E. Tamborini, et al., Toward the molecular dissection of peritoneal pseudomyxoma, *Ann. Oncol.* 27 (11) (2016) 2097–2103.
- [39] J. Canon, K. Rex, A.Y. Saiki, C. Mohr, K. Cooke, D. Bagal, et al., The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity, *Nature* 575 (7781) (2019) 217–223.
- [40] M. Fakih, B. O'Neil, T.J. Price, G.S. Falchook, J. Desai, J. Kuo, et al., Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors, *J. Clin. Oncol.* 37 (15_suppl) (2019) 3003.